Comprehensive molecular profiling of lung adenocarcinoma
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses. High rates of somatic mutation were seen (mean 8.9 mutations per megabase). Eighteen genes were statistically significantly mutated, including RIT1 activating mutations and newly described loss-of-function MGA mutations which are mutually exclusive with focal MYC amplification. EGFR mutations were more frequent in female patients, whereas mutations in RBM10 were more common in males. Aberrations in NF1, MET, ERBB2 and RIT1 occurred in 13% of cases and were enriched in samples otherwise lacking an activated oncogene, suggesting a driver role for these events in certain tumours. DNA and mRNA sequence from the same tumour highlighted splicing alterations driven by somatic genomic changes, including exon 14 skipping in MET mRNA in 4% of cases. MAPK and PI(3)K pathway activity, when measured at the protein level, was explained by known mutations in only a fraction of cases, suggesting additional, unexplained mechanisms of pathway activation. These data establish a foundation for classification and further investigations of lung adenocarcinoma molecular pathogenesis. An integrated transcriptome, genome, methylome and proteome analysis of over 200 lung adenocarcinomas reveals high rates of somatic mutations, 18 statistically significantly mutated genes including RIT1 and MGA, splicing changes, and alterations in MAPK and PI(3)K pathway activity. This report from The Cancer Genome Atlas Research Network presents molecular profiling of 230 resected untreated lung adenocarcinomas. Integrated analyses of transcriptome, genome, methylome and proteome collectively identify high rates of somatic mutation, significantly mutated genes including RIT1 and MGA, splicing alterations driven by somatic genomic changes, and point to as yet unidentified lesions that alter MAPK and PI(3)K pathway activity. These data establish a foundation for classification and further investigations of the leading cause of cancer death worldwide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Landmark large scale sequencing studies have established a census of major KRAS co-mutations in both early-stage and advanced LUAD15, 34, 59, 62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in PIK3CA and CTNNB1 are more frequent in advanced stage tumors compared with early stage LUADs, pointing towards functional roles in malignant progression and metastasis, whereas alterations in TP53 (62.5%), RB1 (9.5 −12.5%) and NKX2–1 (12.5%) appear to occur with comparable frequencies in early- and advanced-stage tumors15, 34, 72, 73.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“earlier studies that identified a central role for WNT signaling in LUAD metastasis”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Van Schil, P. E., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,792
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446 · cited 1×
“Analysis of mutations in PIK3CA and STK11, STK11 protein levels, and AMPK and AKT phosphorylation(33) led to the identification of three major mTOR patterns in lung adenocarcinoma: (1) tumours with minimal or basal mTOR pathway activation, (2) tumours showing higher mTOR activity accompanied by either STK11-inactivati…”
BackgroundComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citationBhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Cited by
Items 301–400 of 1,045
Roles of Nrf2 in cell proliferation and differentiation
Murakami, S., & Motohashi, H. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.030 · Cited by 225
HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence
Fu, J., Su, X., Li, Z., Deng, L., Liu, X., Feng, X., & Peng, J. (2021) · Oncogene · doi:10.1038/s41388-021-01863-w · Cited by 235
Telonis, A. G., Magee, R., Loher, P., Chervoneva, I., Londin, E., & Rigoutsos, I. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx082 · Cited by 224
(2017) · doi:10.1158/2159-8290.cd-17-0256 · Cited by 223
Epigenomic State Transitions Characterize Tumor Progression in Mouse Lung Adenocarcinoma
LaFave, L. M., Kartha, V. K., Ma, S., Meli, K., Del Priore, I., Lareau, C., Naranjo, S., Westcott, P. M. K., Duarte, F. M., Sankar, V., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.006 · Cited by 220
“…with each of the 11 co-accessibility modules were predictive of clinical outcome in human LUAD, we queried them against The Cancer Genome Atlas (TCGA) collection of bulk primary LUAD RNA-seq profiles (n = 506) (Figure 7B) (Campbell et al., 2016; Cancer Genome Atlas Research Network, 2014).”
MethodThe NF1 gene in tumor syndromes and melanoma
Kiuru, M., & Busam, K. J. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2016.142 · Cited by 217
Marinelli, D., Mazzotta, M., Scalera, S., Terrenato, I., Sperati, F., D'Ambrosio, L., Pallocca, M., Corleone, G., Krasniqi, E., Pizzuti, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2105 · Cited by 221
Lu, S., Wu, L., Jian, H., Cheng, Y., Wang, Q., Fang, J., Wang, Z., Hu, Y., Han, L., Sun, M., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00135-2 · Cited by 214
Testing for ROS1 in non-small cell lung cancer: a review with recommendations
Bubendorf, L., Büttner, R., Al-Dayel, F., Dietel, M., Elmberger, G., Kerr, K., López-Ríos, F., Marchetti, A., Öz, B., Pauwels, P., et al. (2016) · Virchows Archiv · doi:10.1007/s00428-016-2000-3 · Cited by 219
Best, S. A., De Souza, D. P., Kersbergen, A., Policheni, A. N., Dayalan, S., Tull, D., Rathi, V., Gray, D. H., Ritchie, M. E., McConville, M. J., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.006 · Cited by 217
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
Foster, S. A., Whalen, D. M., Özen, A., Wongchenko, M. J., Yin, J., Yen, I., Schaefer, G., Mayfield, J. D., Chmielecki, J., Stephens, P. J., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.010 · Cited by 212
Chen, J., Tan, Y., Sun, F., Hou, L., Zhang, C., Ge, T., Yu, H., Wu, C., Zhu, Y., Duan, L., et al. (2020) · Genome Biology · doi:10.1186/s13059-020-02064-6 · Cited by 216
A genome-wide positioning systems network algorithm for in silico drug repurposing
Cheng, F., Lu, W., Liu, C., Fang, J., Hou, Y., Handy, D. E., Wang, R., Zhao, Y., Yang, Y., Huang, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10744-6 · Cited by 215
Rahman, M., Jackson, L. K., Johnson, W. E., Li, D. Y., Bild, A. H., & Piccolo, S. R. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv377 · Cited by 215
What turns CREB on? And off? And why does it matter?
Steven, A., Friedrich, M., Jank, P., Heimer, N., Budczies, J., Denkert, C., & Seliger, B. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03525-8 · Cited by 213
Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation
Lv, L., Chen, P., Cao, L., Li, Y., Zeng, Z., Cui, Y., Wu, Q., Li, J., Wang, J.-H., Dong, M.-Q., et al. (2020) · eLife · doi:10.7554/elife.59994 · Cited by 215
Application of Next Generation Sequencing in Laboratory Medicine
Zhong, Y., Xu, F., Wu, J., Schubert, J., & Li, M. M. (2021) · Annals of Laboratory Medicine · doi:10.3343/alm.2021.41.1.25 · Cited by 215
CellCharter reveals spatial cell niches associated with tissue remodeling and cell plasticity
Varrone, M., Tavernari, D., Santamaria-Martínez, A., Walsh, L. A., & Ciriello, G. (2024) · Nature Genetics · doi:10.1038/s41588-023-01588-4 · Cited by 210
“In multiple independent LUAD cohorts 11,64–71 , the response-to-hypoxia signature was highly correlated with TAN infiltration but showed no correlation with NAN (Fig.”
The origins and genetic interactions of KRAS mutations are allele- and tissue-specific
Cook, J. H., Melloni, G. E. M., Gulhan, D. C., Park, P. J., & Haigis, K. M. (2021) · Nature Communications · doi:10.1038/s41467-021-22125-z · Cited by 208
Becht, E., Giraldo, N. A., Germain, C., de Reyniès, A., Laurent-Puig, P., Zucman-Rossi, J., Dieu-Nosjean, M.-C., Sautès-Fridman, C., & Fridman, W. H. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2015.12.002 · Cited by 213
Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study
Shi, J., Hua, X., Zhu, B., Ravichandran, S., Wang, M., Nguyen, C., Brodie, S. A., Palleschi, A., Alloisio, M., Pariscenti, G., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002162 · Cited by 212
A Selective Review of Multi-Level Omics Data Integration Using Variable Selection
Wu, C., Zhou, F., Ren, J., Li, X., Jiang, Y., & Ma, S. (2019) · High-Throughput · doi:10.3390/ht8010004 · Cited by 213
Precision medicine in non-small cell lung cancer: Current applications and future directions
Yang, S.-R., Schultheis, A. M., Yu, H., Mandelker, D., Ladanyi, M., & Büttner, R. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.009 · Cited by 209
METTL13 Methylation of eEF1A Increases Translational Output to Promote Tumorigenesis
Liu, S., Hausmann, S., Carlson, S. M., Fuentes, M. E., Francis, J. W., Pillai, R., Lofgren, S. M., Hulea, L., Tandoc, K., Lu, J., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.038 · Cited by 210
Multi-omic tumor data reveal diversity of molecular mechanisms that correlate with survival
Ramazzotti, D., Lal, A., Wang, B., Batzoglou, S., & Sidow, A. (2018) · Nature Communications · doi:10.1038/s41467-018-06921-8 · Cited by 212
High-throughput phenotyping of lung cancer somatic mutations
Berger, A. H., Brooks, A. N., Wu, X., Shrestha, Y., Chouinard, C., Piccioni, F., Bagul, M., Kamburov, A., Imielinski, M., Hogstrom, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.022 · Cited by 192
Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model
Zhang, Z., Shiratsuchi, H., Lin, J., Chen, G., Reddy, R. M., Azizi, E., Fouladdel, S., Chang, A. C., Lin, L., Jiang, H., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2592 · Cited by 207
Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer
Heyn, H., Vidal, E., Ferreira, H. J., Vizoso, M., Sayols, S., Gomez, A., Moran, S., Boque-Sastre, R., Guil, S., Martinez-Cardus, A., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-0879-2 · Cited by 208
Zhang, X.-C., Wang, J., Shao, G.-G., Wang, Q., Qu, X., Wang, B., Moy, C., Fan, Y., Albertyn, Z., Huang, X., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09762-1 · Cited by 209
Cancer gene mutation frequencies for the U.S. population
Mendiratta, G., Ke, E., Aziz, M., Liarakos, D., Tong, M., & Stites, E. C. (2021) · Nature Communications · doi:10.1038/s41467-021-26213-y · Cited by 208
Gutierrez, M. E., Choi, K., Lanman, R. B., Licitra, E. J., Skrzypczak, S. M., Pe Benito, R., Wu, T., Arunajadai, S., Kaur, S., Harper, H., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.04.004 · Cited by 208
La Fleur, L., Falk-Sörqvist, E., Smeds, P., Berglund, A., Sundström, M., Mattsson, J. S., Brandén, E., Koyi, H., Isaksson, J., Brunnström, H., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.003 · Cited by 207
Fang, W., Ma, Y., Yin, J. C., Hong, S., Zhou, H., Wang, A., Wang, F., Bao, H., Wu, X., Yang, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0585 · Cited by 207
Noorbakhsh, J., Farahmand, S., Foroughi pour, A., Namburi, S., Caruana, D., Rimm, D., Soltanieh-ha, M., Zarringhalam, K., & Chuang, J. H. (2020) · Nature Communications · doi:10.1038/s41467-020-20030-5 · Cited by 206
Xing, X., Yang, F., Huang, Q., Guo, H., Li, J., Qiu, M., Bai, F., & Wang, J. (2021) · Science Advances · doi:10.1126/sciadv.abd9738 · Cited by 205
Precision Management of Advanced Non–Small Cell Lung Cancer
Yang, C.-Y., Yang, J. C.-H., & Yang, P.-C. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-051718-013524 · Cited by 203
Nong, J., Gong, Y., Guan, Y., Yi, X., Yi, Y., Chang, L., Yang, L., Lv, J., Guo, Z., Jia, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05327-w · Cited by 202
Li, F., Huang, Q., Luster, T. A., Hu, H., Zhang, H., Ng, W.-L., Khodadadi-Jamayran, A., Wang, W., Chen, T., Deng, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0780 · Cited by 203
Genomic–transcriptomic evolution in lung cancer and metastasis
Martínez-Ruiz, C., Black, J. R. M., Puttick, C., Hill, M. S., Demeulemeester, J., Larose Cadieux, E., Thol, K., Jones, T. P., Veeriah, S., Naceur-Lombardelli, C., et al. (2023) · Nature · doi:10.1038/s41586-023-05706-4 · Cited by 201
Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung
Shim, H. S., Kenudson, M., Zheng, Z., Liebers, M., Cha, Y. J., Hoang Ho, Q., Onozato, M., Phi Le, L., Heist, R. S., & Iafrate, A. J. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000579 · Cited by 203
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
Molina-Arcas, M., Moore, C., Rana, S., van Maldegem, F., Mugarza, E., Romero-Clavijo, P., Herbert, E., Horswell, S., Li, L.-S., Janes, M. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw7999 · Cited by 203
Zhang, L., Lv, C., Jin, Y., Cheng, G., Fu, Y., Yuan, D., Tao, Y., Guo, Y., Ni, X., & Shi, T. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00477 · Cited by 203
Zhang, C., Zhang, J., Xu, F.-P., Wang, Y.-G., Xie, Z., Su, J., Dong, S., Nie, Q., Shao, Y., Zhou, Q., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.07.031 · Cited by 203
New clinical trial design in precision medicine: discovery, development and direction
Duan, X.-P., Qin, B.-D., Jiao, X.-D., Liu, K., Wang, Z., & Zang, Y.-S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01760-0 · Cited by 197
Tan, D. S. W., Yom, S. S., Tsao, M. S., Pass, H. I., Kelly, K., Peled, N., Yung, R. C., Wistuba, I. I., Yatabe, Y., Unger, M., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.008 · Cited by 201
Immune microenvironment composition in non‐small cell lung cancer and its association with survival
Tamminga, M., Hiltermann, T. J. N., Schuuring, E., Timens, W., Fehrmann, R. S., & Groen, H. J. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1142 · Cited by 201
Kadara, H., Choi, M., Zhang, J., Parra, E. R., Rodriguez-Canales, J., Gaffney, S. G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw436 · Cited by 200
Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers
Goldstein, L. D., Lee, J., Gnad, F., Klijn, C., Schaub, A., Reeder, J., Daemen, A., Bakalarski, C. E., Holcomb, T., Shames, D. S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.010 · Cited by 200
Eichner, L. J., Brun, S. N., Herzig, S., Young, N. P., Curtis, S. D., Shackelford, D. B., Shokhirev, M. N., Leblanc, M., Vera, L. I., Hutchins, A., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.10.005 · Cited by 198
Riudavets, M., Sullivan, I., Abdayem, P., & Planchard, D. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100260 · Cited by 196
Akbay, E. A., Koyama, S., Liu, Y., Dries, R., Bufe, L. E., Silkes, M., Alam, M. M., Magee, D. M., Jones, R., Jinushi, M., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.017 · Cited by 198
“(B) Expression of IL-17A, granulocyte col and IL-6 in EGFR and Kras-mutant lung cancer samples from Th 75) samples.(1) Expression of IL-17A, colony-stimulating factor sequencing data (p 1⁄4 0.”
Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing
Euskirchen, P., Bielle, F., Labreche, K., Kloosterman, W. P., Rosenberg, S., Daniau, M., Schmitt, C., Masliah-Planchon, J., Bourdeaut, F., Dehais, C., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1743-5 · Cited by 196
Garrido-Martin, E. M., Mellows, T. W. P., Clarke, J., Ganesan, A.-P., Wood, O., Cazaly, A., Seumois, G., Chee, S. J., Alzetani, A., King, E. V., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000778 · Cited by 196
MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma
Qian, Y., Galan-Cobo, A., Guijarro, I., Dang, M., Molkentine, D., Poteete, A., Zhang, F., Wang, Q., Wang, J., Parra, E., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.05.015 · Cited by 193
The pleiotropic functions of reactive oxygen species in cancer
Wu, K., El Zowalaty, A. E., Sayin, V. I., & Papagiannakopoulos, T. (2024) · Nature Cancer · doi:10.1038/s43018-024-00738-9 · Cited by 196
“Mutually exclusive loss-of-function KEAP1 or gain-of-function NRF2 mutations as well as epigenetic or post-transcriptional alterations driving NRF2 hyperactivation are common pro-tumorigenic events across many tumor types 6,7,110 .”
Immune Resistance in Lung Adenocarcinoma
Spella, M., & Stathopoulos, G. T. (2021) · Cancers · doi:10.3390/cancers13030384 · Cited by 193
Cells of origin of lung cancers: lessons from mouse studies
Ferone, G., Lee, M. C., Sage, J., & Berns, A. (2020) · Genes & Development · doi:10.1101/gad.338228.120 · Cited by 196
Santoni-Rugiu, E., Melchior, L. C., Urbanska, E. M., Jakobsen, J. N., de Stricker, K., Grauslund, M., & Sørensen, J. B. (2019) · Cancers · doi:10.3390/cancers11070923 · Cited by 194
IRF4 instructs effector Treg differentiation and immune suppression in human cancer
Alvisi, G., Brummelman, J., Puccio, S., Mazza, E. M. C., Tomada, E. P., Losurdo, A., Zanon, V., Peano, C., Colombo, F. S., Scarpa, A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci130426 · Cited by 195
cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth
Chen, Z., Li, J.-L., Lin, S., Cao, C., Gimbrone, N. T., Yang, R., Fu, D. A., Carper, M. B., Haura, E. B., Schabath, M. B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85250 · Cited by 194
McFadden, D. G., Politi, K., Bhutkar, A., Chen, F. K., Song, X., Pirun, M., Santiago, P. M., Kim-Kiselak, C., Platt, J. T., Lee, E., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613601113 · Cited by 194
Genomic heterogeneity of multiple synchronous lung cancer
Liu, Y., Zhang, J., Li, L., Yin, G., Zhang, J., Zheng, S., Cheung, H., Wu, N., Lu, N., Mao, X., et al. (2016) · Nature Communications · doi:10.1038/ncomms13200 · Cited by 194
Chronic obstructive pulmonary disease (COPD) and lung cancer: common pathways for pathogenesis
Parris, B. A., O’Farrell, H. E., Fong, K. M., & Yang, I. A. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.10.54 · Cited by 194
Molecular Insight of Regorafenib Treatment for Colorectal Cancer
Arai, H., Battaglin, F., Wang, J., Lo, J. H., Soni, S., Zhang, W., & Lenz, H.-J. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101912 · Cited by 191
Vaz, M., Hwang, S. Y., Kagiampakis, I., Phallen, J., Patil, A., O'Hagan, H. M., Murphy, L., Zahnow, C. A., Gabrielson, E., Velculescu, V. E., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.08.006 · Cited by 191
Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers
Hodges, H. C., Stanton, B. Z., Cermakova, K., Chang, C.-Y., Miller, E. L., Kirkland, J. G., Ku, W. L., Veverka, V., Zhao, K., & Crabtree, G. R. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-017-0007-3 · Cited by 190
Ravi, A., Hellmann, M. D., Arniella, M. B., Holton, M., Freeman, S. S., Naranbhai, V., Stewart, C., Leshchiner, I., Kim, J., Akiyama, Y., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01355-5 · Cited by 188
PDXNET Consortium, Woo, X. Y., EurOPDX Consortium, Giordano, J., Srivastava, A., Zhao, Z.-M., Lloyd, M. W., de Bruijn, R., Suh, Y.-S., Patidar, R., et al. (2021) · Nature Genetics · doi:10.1038/s41588-020-00750-6 · Cited by 190
“Whole 227 genome sequencing was conducted as follows: genomic DNA was extracted from breast cancers 228 and corresponding PDXs using (i) QIAamp DNA Mini Kit s(50) (#51304, Qiagen) (IC) or (ii) 229 according to Laird PW’s protocol16 (NKI and VHIO).”
MethodSelf-citationUnni, A. M., Lockwood, W. W., Zejnullahu, K., Lee-Lin, S.-Q., & Varmus, H. (2015) · eLife · doi:10.7554/elife.06907 · Cited by 190
VanderLaan, P. A., Rangachari, D., Mockus, S. M., Spotlow, V., Reddi, H. V., Malcolm, J., Huberman, M. S., Joseph, L. J., Kobayashi, S. S., & Costa, D. B. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.01.011 · Cited by 190
“The use of comprehensive genomic profiling in clinical specimens was able to identify a significant number of concurrent mutations in EGFR mutated lung cancers, confirming the TCGA lung adenocarcinoma data that showed that TP53, PIK3CA and PTEN mutations are frequent concurrent abnormalities [4].”
BackgroundMethodResultInfluentialZhou, M., Leung, A., Echegaray, S., Gentles, A., Shrager, J. B., Jensen, K. C., Berry, G. J., Plevritis, S. K., Rubin, D. L., Napel, S., et al. (2018) · Radiology · doi:10.1148/radiol.2017161845 · Cited by 190
Takahashi, N., Cho, P., Selfors, L. M., Kuiken, H. J., Kaul, R., Fujiwara, T., Harris, I. S., Zhang, T., Gygi, S. P., & Brugge, J. S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.10.010 · Cited by 189
“These mutations are particularly prevalent in non-small cell lung cancer (Collisson et al., 2014; Hammerman et al., 2012), where mutations occur in ~30% of lung squamous cell carcinoma (LUSC) patients and in ~25% of lung adenocarcinoma (LUAD) patients, as well as in other squamous cell carcinomas…”
BackgroundDeciphering cell lineage specification of human lung adenocarcinoma with single-cell RNA sequencing
Wang, Z., Li, Z., Zhou, K., Wang, C., Jiang, L., Zhang, L., Yang, Y., Luo, W., Qiao, W., Wang, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26770-2 · Cited by 185
van Rijt, S. H., Bölükbas, D. A., Argyo, C., Datz, S., Lindner, M., Eickelberg, O., Königshoff, M., Bein, T., & Meiners, S. (2015) · ACS Nano · doi:10.1021/nn5070343 · Cited by 188
MET Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung
Schildhaus, H.-U., Schultheis, A. M., Rüschoff, J., Binot, E., Merkelbach-Bruse, S., Fassunke, J., Schulte, W., Ko, Y.-D., Schlesinger, A., Bos, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0450 · Cited by 188
Advances in Lipidomics for Cancer Biomarkers Discovery
Perrotti, F., Rosa, C., Cicalini, I., Sacchetta, P., Del Boccio, P., Genovesi, D., & Pieragostino, D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17121992 · Cited by 188
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
Xue, Y., Meehan, B., Fu, Z., Wang, X. Q. D., Fiset, P. O., Rieker, R., Levins, C., Kong, T., Zhu, X., Morin, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08380-1 · Cited by 187
Lung Cancer in the Era of Precision Medicine
Politi, K., & Herbst, R. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2748 · Cited by 187
RAS: Striking at the Core of the Oncogenic Circuitry
Gimple, R. C., & Wang, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00965 · Cited by 174
An atlas of epithelial cell states and plasticity in lung adenocarcinoma
Han, G., Sinjab, A., Rahal, Z., Lynch, A. M., Treekitkarnmongkol, W., Liu, Y., Serrano, A. G., Feng, J., Liang, K., Khan, K., et al. (2024) · Nature · doi:10.1038/s41586-024-07113-9 · Cited by 183
Novel therapeutic targets on the horizon for lung cancer
Tan, W.-L., Jain, A., Takano, A., Newell, E. W., Iyer, N. G., Lim, W.-T., Tan, E.-H., Zhai, W., Hillmer, A. M., Tam, W.-L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30123-1 · Cited by 184
Current Landscape of Targeted Therapy in Lung Cancer
Mayekar, M. K., & Bivona, T. G. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.810 · Cited by 183
A body map of somatic mutagenesis in morphologically normal human tissues
Li, R., Di, L., Li, J., Fan, W., Liu, Y., Guo, W., Liu, W., Liu, L., Li, Q., Chen, L., et al. (2021) · Nature · doi:10.1038/s41586-021-03836-1 · Cited by 183
Fujino, T., Kobayashi, Y., Suda, K., Koga, T., Nishino, M., Ohara, S., Chiba, M., Shimoji, M., Tomizawa, K., Takemoto, T., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.06.023 · Cited by 177
Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer
Best, S. A., Gubser, P. M., Sethumadhavan, S., Kersbergen, A., Negrón Abril, Y. L., Goldford, J., Sellers, K., Abeysekera, W., Garnham, A. L., McDonald, J. A., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.04.003 · Cited by 179
Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma
Shukla, S., Evans, J. R., Malik, R., Feng, F. Y., Dhanasekaran, S. M., Cao, X., Chen, G., Beer, D. G., Jiang, H., & Chinnaiyan, A. M. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw200 · Cited by 181
Bunn, P. A., Minna, J. D., Augustyn, A., Gazdar, A. F., Ouadah, Y., Krasnow, M. A., Berns, A., Brambilla, E., Rekhtman, N., Massion, P. P., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.012 · Cited by 181
Zhou, B., Flodby, P., Luo, J., Castillo, D. R., Liu, Y., Yu, F.-X., McConnell, A., Varghese, B., Li, G., Chimge, N.-O., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci90429 · Cited by 180
Multiomic analysis of cytokines in immuno-oncology
Jurisic, V. (2020) · Expert Review of Proteomics · doi:10.1080/14789450.2020.1845654 · Cited by 180
Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer
Fois, S. S., Paliogiannis, P., Zinellu, A., Fois, A. G., Cossu, A., & Palmieri, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020612 · Cited by 180
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype
Della Corte, C. M., Sen, T., Gay, C. M., Ramkumar, K., Diao, L., Cardnell, R. J., Rodriguez, B. L., Stewart, C. A., Papadimitrakopoulou, V. A., Gibson, L., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.009 · Cited by 180
“These observations were then validated in the larger independent TCGA LUAD cohort (n=511, rho>0.6, p 0.001) (Supplemental Figure 1A).”
InfluentialRoper, N., Brown, A.-L., Wei, J. S., Pack, S., Trindade, C., Kim, C., Restifo, O., Gao, S., Sindiri, S., Mehrabadi, F., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100007 · Cited by 180
MicroRNA In Lung Cancer: Novel Biomarkers and Potential Tools for Treatment
Inamura, K., & Ishikawa, Y. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5030036 · Cited by 178
A genetic basis for the variation in the vulnerability of cancer to DNA damage
Yard, B. D., Adams, D. J., Chie, E. K., Tamayo, P., Battaglia, J. S., Gopal, P., Rogacki, K., Pearson, B. E., Phillips, J., Raymond, D. P., et al. (2016) · Nature Communications · doi:10.1038/ncomms11428 · Cited by 175
Yochum, Z. A., Cades, J., Wang, H., Chatterjee, S., Simons, B. W., O’Brien, J. P., Khetarpal, S. K., Lemtiri-Chlieh, G., Myers, K. V., Huang, E. H.-B., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0482-y · Cited by 178
Nilsson, M. B., Sun, H., Robichaux, J., Pfeifer, M., McDermott, U., Travers, J., Diao, L., Xi, Y., Tong, P., Shen, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz4589 · Cited by 177
Russo, A., Franchina, T., Rita Ricciardi, G. R., Picone, A., Ferraro, G., Zanghì, M., Toscano, G., Giordano, A., & Adamo, V. (2015) · Oncotarget · doi:10.18632/oncotarget.4254 · Cited by 173
Sebestyén, E., Zawisza, M., & Eyras, E. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1392 · Cited by 177
Pan-cancer patterns of DNA methylation
Witte, T., Plass, C., & Gerhauser, C. (2014) · Genome Medicine · doi:10.1186/s13073-014-0066-6 · Cited by 175
Nukaga, S., Yasuda, H., Tsuchihara, K., Hamamoto, J., Masuzawa, K., Kawada, I., Naoki, K., Matsumoto, S., Mimaki, S., Ikemura, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2359 · Cited by 175
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2014-07-09
- Volume
- 511
- Issue
- 7511
- Pages
- 543-550
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4231481
- OpenAlex
- W2180481128
- Cited by
- 5,732
- References
- 42
- Citations by year
- 2026: 314 · 2025: 415 · 2024: 428 · 2023: 523 · 2022: 547 · 2021: 614 · 2020: 613 · 2019: 495 · 2018: 478 · 2017: 516 · 2016: 427 · 2015: 312 · 2014: 47
- FWCI
- 347.50
- Type
- journal article
- Language
- en
- Update notices
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc-sa)
- SERVAL (Université de Lausanne) (acceptedVersion, cc-by-nc-sa)
- eScholarship (California Digital Library) (submittedVersion)
- IRIS (submittedVersion, cc-by-nc-sa)
- eSpace (Curtin University) (submittedVersion)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (UL1TR000005)
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273, R01HG006272)
- National Cancer Institute (U24CA126554, U24CA143882, U24CA143843, U24CA143840, U24CA126546, CA143883, U24CA143858, K08CA137153, U24CA126543, U24CA144025, U24CA126563, U24CA143866, U24CA143883, CA143840, U24 CA137153, U24CA143845, U24CA126544, U24CA180951, U24CA143867, U24CA143848, U24CA143799, U24CA126551, U24CA143835, U24CA126561, P30CA177558, P30CA008748, P30CA016672, P30CA006973)
- National Institute of General Medical Sciences (T32GM007753)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung adenocarcinoma, somatic mutations, RIT1, MGA, MYC amplification, EGFR mutation, RBM10, neurofibromatosis type 1, MET, ERBB2, MET exon 14 skipping, splicing alterations, MAPK signaling, PI3K signaling, DNA methylation, microRNA, transcriptome, proteome, molecular classification, carcinogenesis
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Female, Humans, Lung Neoplasms, Male, Mutation, Oncogenes, Sex Factors, Gene Expression Regulation, Neoplastic, Gene Dosage, Cell Cycle Proteins, Genomics, Molecular Typing, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.